

# Parakkal Deepak

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9577375/parakkal-deepak-publications-by-citations.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

104 papers	2,010 citations	22 h-index	42 g-index
178 ext. papers	2,864 ext. citations	4.6 avg, IF	5.24 L-index

#	Paper	IF	Citations
104	Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. <i>Nature Medicine</i> , <b>2021</b> , 27, 717-726	50.5	497
103	T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF)-inhibitors: results of the REFURBISH study. <i>American Journal of Gastroenterology</i> , <b>2013</b> , 108, 99-105	0.7	155
102	Hepatosplenic T-cell lymphoma in patients receiving TNF-inhibitor therapy: expanding the groups at risk. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2011</b> , 23, 1150-6	2.2	87
101	Radiological Response Is Associated With Better Long-Term Outcomes and Is a Potential Treatment Target in Patients With Small Bowel Crohn's Disease. <i>American Journal of Gastroenterology</i> , <b>2016</b> , 111, 997-1006	0.7	82
100	Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, 1572-1585	8	80
99	Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 38, 388-96	6.1	59
98	The metoclopramide black box warning for tardive dyskinesia: effect on clinical practice, adverse event reporting, and prescription drug lawsuits. <i>American Journal of Gastroenterology</i> , <b>2013</b> , 108, 866-72	0.7	54
97	Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2 <b>2021</b> ,		44
96	Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System. <i>Journal of Gastrointestinal and Liver Diseases</i> , <b>2014</b> , 23, 267-71	1.4	43
95	is enriched in Crohn's disease intestinal tissue and impairs healing in mice. <i>Science</i> , <b>2021</b> , 371, 1154-1159	33.3	42
94	Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease. <i>Gastroenterology Clinics of North America</i> , <b>2017</b> , 46, 603-626	4.4	40
93	Ustekinumab Is Effective for the Treatment of Crohn's Disease of the Pouch in a Multicenter Cohort. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 767-774	4.5	39
92	SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies <b>2021</b> ,		39
91	Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , <b>2021</b> , 102927	13.6	34
90	Incremental diagnostic yield of chromoendoscopy and outcomes in inflammatory bowel disease patients with a history of colorectal dysplasia on white-light endoscopy. <i>Gastrointestinal Endoscopy</i> , <b>2016</b> , 83, 1005-12	5.2	32
89	Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy. <i>Drug Design, Development and Therapy</i> , <b>2016</b> , 10, 3685-3698	4.4	30
88	Efficacy of Vedolizumab for Refractory Pouchitis of the Ileo-anal Pouch: Results From a Multicenter US Cohort. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 1569-1576	4.5	29

87	Computed Tomography and Magnetic Resonance Enterography in Crohn's Disease: Assessment of Radiologic Criteria and Endpoints for Clinical Practice and Trials. <i>Inflammatory Bowel Diseases</i> , <b>2016</b> , 22, 2280-8	4.5	29
86	Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 40, 1035-43	6.1	27
85	Increased risk of osteoporosis-related fractures in patients with irritable bowel syndrome. <i>Osteoporosis International</i> , <b>2013</b> , 24, 1169-75	5.3	26
84	Radiographical evaluation of ulcerative colitis. <i>Gastroenterology Report</i> , <b>2014</b> , 2, 169-77	3.3	26
83	Infectious complications of TNF-inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System. <i>Journal of Gastrointestinal and Liver Diseases</i> , <b>2013</b> , 22, 269-76	1.4	23
82	Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 1592-1601.e3	6.9	22
81	Alleged isotretinoin-associated inflammatory bowel disease: disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System. <i>Journal of the American Academy of Dermatology</i> , <b>2013</b> , 69, 393-8	4.5	21
80	Hospitalizations for vaccine preventable pneumonias in patients with inflammatory bowel disease: a 6-year analysis of the Nationwide Inpatient Sample. <i>Clinical and Experimental Gastroenterology</i> , <b>2013</b> , 6, 43-9	3.1	21
79	The Role of the Radiologist in Determining Disease Severity in Inflammatory Bowel Diseases. <i>Gastrointestinal Endoscopy Clinics of North America</i> , <b>2019</b> , 29, 447-470	3.3	20
78	Relationship between mesenteric abnormalities on computed tomography and malignancy: clinical findings and outcomes of 359 patients. <i>Journal of Clinical Gastroenterology</i> , <b>2013</b> , 47, 409-14	3	20
77	Renal risks of sodium phosphate tablets for colonoscopy preparation: a review of adverse drug reactions reported to the US Food and Drug Administration. <i>Colorectal Disease</i> , <b>2011</b> , 13, e270-5	2.1	17
76	De-novo Inflammatory Bowel Disease After Bariatric Surgery: A Large Case Series. <i>Journal of Crohn's and Colitis</i> , <b>2018</b> , 12, 452-457	1.5	16
75	Crohn's disease diagnosis, treatment approach, and management paradigm: what the radiologist needs to know. <i>Abdominal Radiology</i> , <b>2017</b> , 42, 1068-1086	3	15
74	Do gastroenterologists adhere to diagnostic and treatment guidelines for celiac disease?. <i>Journal of Clinical Gastroenterology</i> , <b>2012</b> , 46, e12-20	3	15
73	Lubiprostone induced ischemic colitis. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 299-303	5.6	15
72	Successful Treatment of Pyoderma Gangrenosum with Concomitant Tofacitinib and Infliximab. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, e87-e88	4.5	14
71	Bariatric Surgery Is Acceptably Safe in Obese Inflammatory Bowel Disease Patients: Analysis of the Nationwide Inpatient Sample. <i>Obesity Surgery</i> , <b>2018</b> , 28, 1007-1014	3.7	14
70	Ischemic colitis with type I interferons used in the treatment of hepatitis C and multiple sclerosis: an evaluation from the food and drug administration adverse event reporting system and review of the literature. <i>Annals of Pharmacotherapy</i> , <b>2013</b> , 47, 537-42	2.9	14

69	Diffusion-weighted MRI in inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 433-443	18.8	13
68	Isolated Acute Terminal Ileitis Without Preexisting Inflammatory Bowel Disease Rarely Progresses to Crohn's Disease. <i>Digestive Diseases and Sciences</i> , <b>2017</b> , 62, 3557-3562	4	12
67	Assessing the likelihood of new-onset inflammatory bowel disease following tumor necrosis factor-alpha inhibitor therapy for rheumatoid arthritis and juvenile rheumatoid arthritis. <i>Rheumatology International</i> , <b>2015</b> , 35, 661-8	3.6	12
66	Phenotype and Clinical Course of Inflammatory Bowel Disease With Co-existent Celiac Disease. <i>Journal of Crohn's and Colitis</i> , <b>2018</b> , 12, 973-980	1.5	12
65	Ischaemic colitis in rheumatoid arthritis patients receiving tumour necrosis factor-inhibitors: an analysis of reports to the US FDA Adverse Event Reporting System. <i>Drug Safety</i> , <b>2013</b> , 36, 329-34	5.1	12
64	Predictors of Durability of Radiological Response in Patients With Small Bowel Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , <b>2018</b> , 24, 1815-1825	4.5	11
63	Volvulus of the ileal pouch-anal anastomosis: a meta-narrative systematic review of frequency, diagnosis, and treatment outcomes. <i>Gastroenterology Report</i> , <b>2019</b> , 7, 403-410	3.3	11
62	Anti-Tumour Necrosis Factor Therapy for Inflammatory Bowel Diseases Do Not Impact Serious Infections after Arthroplasty. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, 182-188	1.5	11
61	Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 2207-2209.e3	6.9	10
60	Novel Imaging Approaches in Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 248-250	4.5	9
59	Update on the Medical Management of Crohn's Disease. <i>Current Gastroenterology Reports</i> , <b>2015</b> , 17, 41	5	8
58	Effect of tumor necrosis factor-inhibitors on drug-induced pancreatitis in inflammatory bowel disease. <i>Annals of Pharmacotherapy</i> , <b>2014</b> , 48, 1282-7	2.9	8
57	Diarrhea. <i>Disease-a-Month</i> , <b>2011</b> , 57, 490-510	4.4	8
56	Reduced antibody activity against SARS-CoV-2 B.1.617.2 Delta virus in serum of mRNA-vaccinated patients receiving Tumor Necrosis Factor-inhibitors. <i>Med</i> , <b>2021</b> ,	31.7	8
55	Ischemic colitis masquerading as colonic tumor: case report with review of literature. <i>World Journal of Gastroenterology</i> , <b>2011</b> , 17, 5324-6	5.6	8
54	Crohn's Disease Is Associated With an Increased Prevalence of Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study Using Magnetic Resonance Proton Density Fat Fraction Mapping. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2816-2818	6.9	7
53	P344 Real-world effectiveness of tofacitinib in ulcerative colitis: a multi-centre study. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, S274-S275	1.5	7
52	Imaging Findings of Ileal Inflammation at Computed Tomography and Magnetic Resonance Enterography: What do They Mean When Ileoscopy and Biopsy are Negative?. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, 455-464	1.5	7

51	Impact of Bariatric Surgery on the Long-term Disease Course of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , <b>2020</b> , 26, 1089-1097	4.5	7
50	Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, 1431-1442	1.5	7
49	Magnetic resonance enterography features of small bowel Crohn's disease activity: an inter-rater reliability study of small bowel active inflammation in clinical practice setting. <i>British Journal of Radiology</i> , <b>2019</b> , 92, 20180930	3.4	6
48	Constipation. <i>Disease-a-Month</i> , <b>2011</b> , 57, 511-7	4.4	6
47	Calcium phosphate nephropathy from colonoscopy preparations: effect of body weight. <i>American Journal of Gastroenterology</i> , <b>2010</b> , 105, 705	0.7	6
46	Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease. <i>Gastroenterology</i> , <b>2021</b> , 161, 394-399	13.3	6
45	796 Real-World Effectiveness of Tofacitinib in Ulcerative Colitis; a Multi-Center Study. <i>Gastroenterology</i> , <b>2019</b> , 156, S-168-S-169	13.3	5
44	Transmural Healing and MRI Remission: New Promising Therapeutic Targets in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 23, E44-E45	4.5	4
43	Esophageal small cell carcinoma with synchronous renal cell carcinoma: a case report with review of the literature. <i>Case Reports in Gastroenterology</i> , <b>2011</b> , 5, 196-200	1	4
42	Multiphase Computed Tomographic Enterography: Diagnostic Yield and Efficacy in Patients With Suspected Small Bowel Bleeding. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , <b>2019</b> , 3, 438-447	3.1	4
41	Simulated comparison of topical and oral formulations of 5-aminosalicylate for the treatment of ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , <b>2013</b> , 19, 301-8	4.5	3
40	Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease.. <i>Crohn's &amp; Colitis 360</i> , <b>2022</b> , 4, otac002	1.4	3
39	Effect of Comorbid Celiac Disease on Hospitalized Patients with Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , <b>2013</b> , 108, S519	0.7	3
38	Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic Fatty Liver Disease in Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , <b>2020</b> , 26, 1917-1925	4.5	3
37	797 Real-World Safety of Tofacitinib in Inflammatory Bowel Diseases: A Multi-Center Study. <i>Gastroenterology</i> , <b>2019</b> , 156, S-169	13.3	2
36	An Analysis of Hospital Charges and Length of Stay in Patients with Eosinophilic Esophagitis Admitted for Foreign Body in the Esophagus. <i>American Journal of Gastroenterology</i> , <b>2013</b> , 108, S12-S13	0.7	2
35	Use of polyethylene glycol-based colonoscopy preparations before rectal argon plasma coagulation: lessons still to be learned by practicing gastroenterologists. <i>Journal of Clinical Gastroenterology</i> , <b>2012</b> , 46, 803-4	3	2
34	Postprandial Chylomicron Output and Transport Through Intestinal Lymphatics Are Not Impaired in Active Crohn's Disease. <i>Gastroenterology</i> , <b>2020</b> , 159, 1955-1957.e2	13.3	2

33	Risk of Myeloid Neoplasms in Inflammatory Bowel Disease Patients Is Linked to Exposure to Thiopurines and Not With Tumor Necrosis Factor- $\alpha$ Inhibitors. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 1857-8	6.9	1
32	Reply to the Letter to the Editor: Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic Fatty Liver Disease in Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , <b>2020</b> , 26, e46	4.5	1
31	Beyond the Label: Ensuring That Drug Benefits Outweigh Risks in the Food and Drug Administration's Risk Evaluation and Mitigation Strategy Program. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 1017-1019	0.7	1
30	S933 Risk Factors for Cardiovascular Diseases in Participants With Inflammatory Bowel Diseases: Analysis of the United Kingdom Biobank. <i>American Journal of Gastroenterology</i> , <b>2021</b> , 116, S443-S443	0.7	1
29	Addressing unmet needs from a new frontier of IBD: the South Asian IBD Alliance. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2021</b> , 6, 884-885	18.8	1
28	Disease and Treatment Patterns Among Patients With Pouch-related Conditions in a Cohort of Large Tertiary Care Inflammatory Bowel Disease Centers in the United States. <i>Crohn's &amp; Colitis 360</i> , <b>2020</b> , 2, otaa039	1.4	1
27	S0897 Efficacy and Safety of Combining Tofacitinib With a Biologic in Patients With Refractory Inflammatory Bowel Diseases. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, S461-S462	0.7	1
26	Pouchitis: Bile Acid Deficiency Links Inflammation to Dysbiosis. <i>Gastroenterology</i> , <b>2020</b> , 159, 1615-1616	13.3	1
25	Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , <b>2021</b> , 66, 3563-3569	4	1
24	Multidisciplinary management of perianal Crohn's disease. <i>Current Opinion in Gastroenterology</i> , <b>2021</b> , 37, 295-305	3	1
23	Effectiveness and Safety of Combining Tofacitinib With a Biologic in Patients With Refractory Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, 1698-1702	4.5	1
22	Mucinous Small Bowel Adenocarcinoma Mimicking Change to Internal Penetrating Phenotype in Well-controlled Crohn's Disease. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 1732-1733	0.7	1
21	Reduced antibody activity against SARS-CoV-2 B.1.617.2 Delta virus in serum of mRNA-vaccinated patients receiving TNF-inhibitors		1
20	Other effects on the colon. <i>Disease-a-Month</i> , <b>2011</b> , 57, 518-23	4.4	0
19	783 Nonalcoholic Fatty Liver Disease in a South Asian Crohn's Disease Population: External Validation of the St. Louis Steatosis Index. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, S453-S454	0.7	0
18	Lower body weight and female gender: hyperphosphatemia risk factors after sodium phosphate preparations. <i>World Journal of Gastroenterology</i> , <b>2011</b> , 17, 2681-2	5.6	0
17	Inflammatory Bowel Disease, Celiac Disease, and Primary Sclerosing Cholangitis: Is There a Link?. <i>Gastroenterology</i> , <b>2021</b> , 160, 2207	13.3	0
16	MRE Evaluation of Intestinal Inflammation: Qualitative and Quantitative Assessment. <i>Topics in Magnetic Resonance Imaging</i> , <b>2021</b> , 30, 13-22	2.3	0



15	P407 Real-world safety of tofacitinib in inflammatory bowel diseases: a multi-centre study. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, S312-S313	1.5
14	Concomitant antibiotic usage does not augment the risk of inflammatory bowel disease with isotretinoin treatment for acne: a review of the Food and Drug Administration Adverse Event Reporting System. <i>European Journal of Clinical Pharmacology</i> , <b>2013</b> , 69, 1041-2	2.8
13	Vitamin D Deficiency Correlates With Primary Sclerosing Cholangitis Disease Severity in Patients With Coexistent Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, S514-S515	0.7
12	Method for the current review. <i>Disease-a-Month</i> , <b>2011</b> , 57, 456	4.4
11	Duodenal diverticulitis: a rare cause of abnormal liver function tests. <i>Endoscopy</i> , <b>2012</b> , 44 Suppl 2 UCTN, E252-3	3.4
10	S967 The Correlation Between Visceral Abdominal and Total Adipose Tissue With Metabolic Risk Factors in Patients With Inflammatory Bowel Diseases. <i>American Journal of Gastroenterology</i> , <b>2021</b> , 116, S463-S463	0.7
9	686 Neither Obesity nor Hepatic Steatosis Are Associated With an Increased Prevalent or Incident Colonic Dysplasia in Patients With Inflammatory Bowel Disease and Concomitant Primary Sclerosing Cholangitis. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, S402-S403	0.7
8	Evaluation of Nonalcoholic Fatty Liver Disease in Pediatric Patients With Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2021</b> , 72, 574-578	2.8
7	Assessment of Gender and Racial Disparities in Quality of Care Indicators for Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, S604	0.7
6	P584 Mucosal Eosinophilia is an Independent Predictor of Vedolizumab Effectiveness in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, S537-S537	1.5
5	P-113 YI Body Fat and Skeletal Muscle Composition Differs in Crohn's Disease Patients Depending on Radiological Response to Medical Therapy. <i>Inflammatory Bowel Diseases</i> , <b>2016</b> , 22, S45	4.5
4	784 A Population-Based Analysis of Obesity, Metabolic Syndrome, and Cardiovascular Outcomes Among Patients With Inflammatory Bowel Disease in the National Health and Nutrition Examination Survey 2009-2010. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, S454-S454	0.7
3	1108 Alkaline Phosphatase Levels Are Negatively Correlated With the Severity of Hepatic Steatosis in Patients With Primary Sclerosing Cholangitis. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, S624-S625	0.7
2	Medical and Endoscopic Management of Crohn Disease. <i>Topics in Magnetic Resonance Imaging</i> , <b>2021</b> , 30, 43-61	2.3
1	Role of Abdominal Imaging in the Diagnosis of IBD Strictures, Fistulas, and Postoperative Complications <b>2018</b> , 79-95	